Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus. A 52-week Randomised, Open-label, Active-controlled Trial
Phase of Trial: Phase III
Latest Information Update: 21 May 2018
At a glance
- Drugs Semaglutide (Primary) ; Empagliflozin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 2
- Sponsors Novo Nordisk
- 23 Mar 2018 Status changed from active, no longer recruiting to completed.
- 19 Mar 2018 This trial has been completed in Spain (end date: 2018-03-08)
- 21 Nov 2017 According to a Novo Nordisk media release, the trial is expected to be completed in 2018.